Tradestie Institutional Equity Comparison Engine

INCR vs BHST โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

INCR Overall Edge

INCR Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Intercure Ltd. Ordinary Shares (INCR) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, INCR trades at 6.2x Forward P/E with 0.0% operating margin (+23.9% YoY revenue) versus BHST at N/M Forward P/E and -18.0% operating margin (+3.8% YoY). In options structure, INCR sits in BREAKDOWN (<1st %ile IV; Dealer Gamma Walls on Pro) against BHST sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner INCR
INCR 6.2x vs BHST N/M Fwd P/E
Growth & Margin Winner INCR
Op Margin 0.0% vs -18.0% ยท YoY +23.9% vs +3.8%
Momentum & Technical Winner INCR
1Y +136.7% vs -79.4% ยท 52W Pos 47% vs 6%
Options & Structure Winner INCR
BREAKDOWN (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
INCR NASDAQ
Intercure Ltd. Ordinary Shares
Pharmaceutical Preparations
$3.24
-7.16% 1D
Market Cap $45.5M
1M Return -26.86%
1Y Return +136.67%
Forward P/E 6.2x
Unified AI Score
66.8 / 100 BUY
Tech 68.0 Fund 62.0 Flow 58.0 Mom 60.0
BHST NASDAQ
BioHarvest Sciences Inc. Common Stock
Pharmaceutical Preparations
$1.30
-1.52% 1D
Market Cap $29.9M
1M Return -22.62%
1Y Return -79.4%
Forward P/E N/M
Unified AI Score
58.2 / 100 HOLD
Tech 75.0 Fund 57.0 Flow 50.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: INCR +136.67% BHST -79.4% Spread: +221.19 pp (INCR Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
INCR TTM Op. Margin: 0.0% BHST TTM Op. Margin: -18.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INCR vs BHST. Trailing 12-month operating profitability (INCR 0.0% vs BHST -18.0%) and valuation multiples (INCR 6.2x vs BHST N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: INCR (10) vs BHST (0)
Institutional Metric INCR BHST Criterion Row Winner
Market Capitalization Scale $45.5M $29.9M Larger Scale INCR
Trailing P/E Ratio Valuation 6.2x N/M Lower Multiple INCR
Forward P/E Ratio Valuation 6.2x N/M Lower Multiple INCR
Revenue Growth (YoY) Growth +23.9% +3.8% Higher Growth INCR
Operating Margin (TTM) Profitability 0.0% -18.0% Higher Margin INCR
Net Profit Margin Profitability -13.2% -31.2% Higher Margin INCR
Return on Equity (ROE) Capital Efficiency -9.3% -142.5% Higher ROE INCR
52-Week Range Position Momentum 47% ($1โ€“$6) 6% ($1โ€“$7) Stronger Trend INCR
Beta / 30D Volatility Risk Regime 0.07ฮฒ ยท 80% Vol 0.25ฮฒ ยท 86% Vol Lower Realized Risk INCR
Unified Institutional Score Composite Signal 66.8 / 100 (BUY) 58.2 / 100 (HOLD) Higher Composite INCR

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full INCR vs BHST Buy Guide
INCR BREAKDOWN
59d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live INCR Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BHST UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live BHST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither INCR nor BHST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.